Business Parks & Science Centres

 
 
 

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Phenex Pharmaceuticals AG

Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a research site in Heidelberg. The company focuses on novel attractive nuclear receptor targets to develop innovative small molecule therapeutics in the fields of liver diseases / NASH (FXR program) and in autoimmune diseases (RORgt program). Phenex´ most advanced program is the FXR agonist Px-102 with which two phase I studies have just been finished. Px-102 targets the nuclear bile acid receptor FXR. This FXR agonist has unique properties in that it shows beneficial effects in lipid lowering, in improving insulin sensitivity, in reducing body weight and in ameliorating the liver inflammation and fibrosis that is a hallmark of Non-Alcoholic Steatohepatitis (NASH). NASH is a metabolically induced liver disease with a worldwide prevalence of at least 25 million affected individuals. If untreated, the disease can progress towards liver cirrhosis and liver failure or to Hepatocellular Carcinoma (HCC). There is no approved treatment for NASH. Px-102 addresses this medical need and represents a significant commercial opportunity. Phenex second program at preclinical stage targets RORgamma-t. RORgamma-t (RORgt) is a Nuclear Receptor that was recently identified as a key differentiation factor of so-called Th17 cells, immune cells that produce and secrete Interleukin-17 which is believed to be a key player in chronic autoimmune-related inflammation. The relevance of the IL-17 pathway has been highlighted by the clinical success of the anti-IL-17 or the anti-IL-12/IL-23 antibodies that all have demonstrated superior efficacy in reducing symptoms in patients with moderate to severe psoriasis. RORgt binds endogenous small molecules and induces the production of IL-17, thus small molecule inhibitors of RORgt have the potential to block the IL-17 pathway in a similar fashion than the antibodies but with potentially fewer side effects combined with the typical advantages of a classical small molecule drug. The effectiveness of inhibiting the IL-17 pathway through small molecule RORgt inhibitors was recently demonstrated in animal models in two adjacent publications in Nature. Phenex is now financed through four consecutive rounds of funding totalling the money raised to 22 million Euros. The circle of investors into Phenex encompasses EVP Capital Partners/VRP, LBBW Venture, Creathor Venture, CD Venture, KfW as well as private individuals and key persons from the pharmaceutical and high-tech industry. *

 

Period Start 2002-10-01 splitoff
  Predecessor Lion Bioscience AG
Products Industry pharmaceutical
  Industry 2 drug discovery services
Persons Person Kremoser, Claus (Phenex 201106 CEO)
  Person 2 Hoffmann, Thomas (Phenex 201106 CFO)
     
Region Region Ludwigshafen
  Country Germany
  Street 1 Donnersbergweg
  City 67059 Ludwigshafen
  Tel +49-621-671960-0
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Phenex Pharmaceuticals AG. (10/31/12). "Press Release: Phenex Reports Successful Completion of Phase I Studies with FXR-Agonist Px-102 and Publishes Research Progress in Two Independent Papers". Ludwigshafen.
     
   
Record changed: 2019-04-11

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Phenex Pharmaceuticals AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top